The purpose of this study was to determine the impact of obesity on clinicopathological features and biochemical recurrence (BCR) following radical prostatectomy (RP) in Korean prostate cancer (PCa) patients.
A single-institutional retrospective analysis was performed on 880 PCa patients treated by RP without neoadjuvant therapy between July 2005 and December 2011. Patients were stratified according to body mass index (BMI) standards for Asian populations: obese (BMI ≥25 kg/m2), overweight (BMI 23–24.9 kg/m2), or normal weight (BMI <23 kg/m2). For analysis, overweight and obese patients were combined (n = 592, BMI ≥23 kg/m2) and compared with normal weight patients (n = 288, BMI <23 kg/m2). BCR was defined as prostate-specific antigen (PSA) ≥0.2 ng/ml following RP.
Normal weight patients tended to be classified into the higher D’Amico risk category with smaller prostate volumes compared with obese and overweight patients. Normal weight patients had higher pathological Gleason scores and were at higher risk of BCR during the mean follow-up of 58.2 months. This translated to a higher 5-year BCR-free survival rate for obese and overweight patients compared with normal weight patients (77.8 vs. 70.3 %; p = 0.017). On multiple Cox-proportional hazards regression analysis incorporating variables of BMI category, PSA, positive surgical margins, pathological T stage, and Gleason score, higher BMI category remained a significant predictor of a lower risk of BCR (HR = 0.634, p = 0.028).
Obese and overweight Korean PCa patients have lower Gleason scores and a reduced risk of BCR compared with normal weight patients. These findings suggest that body fat influences pathological features and oncologic outcomes of PCa.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Ando R, Nagaya T, Hashimoto Y et al (2008) Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004–2006. Urology 72:561–565
World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1–253
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150
GLOBOCAN (2008) IARC. http://globocan.iarc.fr/. Accessed 11 Aug 2012
Tomaszewski JJ, Chen YF, Bertolet M et al (2013) Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy. Urology 81:992–996
Freedland SJ, Isaacs WB, Mangold LA et al (2005) Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 11:2883–2888
Amling CL, Kane CJ, Riffenburgh RH et al (2001) Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58:723–728
Narita S, Mitsuzuka K, Yoneyama T et al (2013) Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 16:271–276
Giovannucci E, Rimm EB, Colditz GA et al (1993) A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571–1579
WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163
Bassett WW, Cooperberg MR, Sadetsky N et al (2005) Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66:1060–1065
Chun FK, Briganti A, Graefen M et al (2007) Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. Eur J Cancer 43:375–382
Isbarn H, Jeldres C, Budaus L et al (2009) Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Urology 73:615–619
Gallina A, Karakiewicz PI, Hutterer GC et al (2007) Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer 121:791–795
Freedland SJ, Aronson WJ, Kane CJ et al (2004) Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22:446–453
Ribeiro DL, Pinto ME, Rafacho A et al (2012) High-fat diet obesity associated with insulin resistance increases cell proliferation, estrogen receptor, and PI3 K proteins in rat ventral prostate. J Androl 33:854–865
Landstrom M, Zhang JX, Hallmans G et al (1998) Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate 36:151–161
Holt SK, Kwon EM, Fu R et al (2013) Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 73:1–10
Kennelly R, Kavanagh DO, Hogan AM et al (2008) Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 9:385–391
Tomicek NJ, Lancaster TS, Korzick DH (2011) Increased estrogen receptor beta in adipose tissue is associated with increased intracellular and reduced circulating adiponectin protein levels in aged female rats. Gend Med 8:325–333
Honma N, Yamamoto K, Ohnaka K et al (2013) Estrogen receptor-beta gene polymorphism and colorectal cancer risk: effect modified by body mass index and isoflavone intake. Int J Cancer 132:951–958
Thelen P, Wuttke W, Seidlova-Wuttke D (2013) Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol. doi:10.1016/j.jsbmb.2013.06.009
Dey P, Strom A, Gustafsson JA (2013) Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. doi:10.1038/onc.2013.384
Turner JV, Agatonovic-Kustrin S, Glass BD (2007) Molecular aspects of phytoestrogen selective binding at estrogen receptors. J Pharm Sci 96:1879–1885
Andres S, Abraham K, Appel KE et al (2011) Risks and benefits of dietary isoflavones for cancer. Crit Rev Toxicol 41:463–506
Hedelin M, Bälter KA, Chang ET et al (2006) Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 66:1512–1520
Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20:3001–3015
Parsons JK, Carter HB, Platz EA et al (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14:2257–2260
Wake DJ, Strand M, Rask E et al (2007) Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol 66:440–446
Deurenberg P, Deurenberg-Yap M, Guricci S (2002) Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev 3:141–146
Conflict of interest
About this article
Cite this article
Koo, K.C., Yoon, Y.E., Rha, K.H. et al. Low body mass index is associated with adverse oncological outcomes following radical prostatectomy in Korean prostate cancer patients. Int Urol Nephrol 46, 1935–1940 (2014). https://doi.org/10.1007/s11255-014-0729-7
- Body mass index
- Prostate cancer
- Treatment outcome